Glebors Global Finance has always advocated the entrepreneurial spirit of pioneering, adventurous and hardworking. Relying on the unique perspective, Glebors has launched various special issues in terms of the economy and finance, which has provided much more assistance to government decision-makers and business leaders.
Currently, AI technology is deeply penetrating all areas of healthcare, profoundly driving the transformation of the global medical system from "experience-driven" to "data-driven". AI in healthcare has gradually advanced from the technology verification phase to a new stage of large-scale deployment, achieving a paradigm shift from "auxiliary diagnosis and treatment tools" to "core decision-making engines". It has become a key breakthrough in tackling the uneven distribution of global medical resources, enhancing the accuracy and efficiency of diagnosis and treatment, as well as reducing medical costs, while demonstrating distinct characteristics of differentiated development and coordinated progress worldwide. To be honest, the industry is undergoing explosive growth.
From a global market perspective, AI in healthcare has formed a "tripartite balance" pattern, with each region exhibiting differentiated development features based on its inherent advantages. North America takes a leading position, supported by a sound medical payment system, advanced technological R&D capabilities, as well as a robust industrial ecosystem, which accounts for 45.6% of the global market in 2025. The U.S. FDA has approved hundreds of AI-related medical devices and applications to date. Tech giants such as OpenAI and Google have actively invested in medical-specific large models, focusing on core areas including clinical decision support and multimodal medical data processing.
Europe adheres to core principle which is "safety-first, standardized development" to regulate the application of AI in healthcare through a rigorous regulatory framework. The EU AI Act explicitly classifies radiological AI systems as high-risk categories, while proactively promoting the popularization and implementation of AI technology in scenarios such as public health monitoring and chronic disease management. The Asia-Pacific region has emerged as the fastest-growing market for AI in healthcare globally. As the core growth engine, China's market size exceeded 115.7 billion yuan in 2025, with the penetration rate of AI in primary healthcare continuing to accelerate, forging a distinctive implementation model tailored to local medical needs.
In core application areas, global AI in healthcare has achieved in-depth breakthroughs across multiple scenarios, comprehensively reshaping the entire diagnosis and treatment process. In the field of diagnosis, interpretable AI technology has made critical breakthroughs. The DeepRare rare disease diagnosis system developed in China achieves an initial diagnosis accuracy of 57.18% based solely on clinical symptoms and currently serves over 600 hospitals worldwide; the AI diagnosis system developed by Google DeepMind reduces the missed diagnosis rate of breast cancer by 5.7%, with diagnostic efficiency significantly outperforming that of traditional radiologists.
In the field of treatment, surgical robots have entered the 4.0 era. The tactile feedback delay of the Da Vinci XI surgical system has been reduced to 5 milliseconds, greatly improving operational precision; China's Tumai remote surgical system has successfully realized remote surgical operations in a 5G environment, filling the technical gap in related domestic fields. In drug R&D, the application of AI technology has drastically shortened the R&D cycle, reducing the development time of lead compounds from several years to one month. The launch of professional platforms such as Insilico Medicine and Huawei Pangu has propelled drug R&D into a "predictive and efficient" era of innovation.
The rapid development of global AI in healthcare not only highlights the value of cross-regional coordinated development but confronts more challenges ahead. In terms of coordinated development, countries around the world actively conduct technological cooperation and cross-border data sharing to drive collaborative industrial upgrading. For instance, Illumina, in conjunction with numerous global pharmaceutical companies, launched the one-billion-cell atlas project, effectively accelerating the drug discovery process; China's AI medical products have been successfully exported to many countries and regions, facilitating the global application of technological achievements. In terms of challenges, data privacy protection and ethical supervision are issues faced globally. Differences in norms such as liability identification and data security standards for AI in healthcare across countries and regions impede the efficiency of cross-regional collaboration and technological deployment. Additionally, issues such as technical bias and the digital divide hinder the popularization of AI in healthcare, with some developing countries struggling to fully benefit from AI-driven medical advancements due to insufficient technical reserves and funding shortages. Looking ahead, global AI in healthcare will steadily advance towards precision, inclusiveness and intelligence. Embodied intelligent medical robots and specialized AI model clusters will emerge as key priorities for industry development. Medical robots with millimeter-level operational precision will gradually be capable of complex procedures such as autonomous puncture and biopsy; lightweight AI models will sink into primary healthcare scenarios with the support of 5G technology. It is estimated that by 2028, the AI application in global county-level hospitals will reach 85%. Meanwhile, countries will further strengthen regulatory coordination, improve AI medical ethics norms and industry standards, and promote the transformation of AI in healthcare from "technological breakthrough" to "in-depth clinical implementation". This will enable AI to truly serve as the core engine driving the high-quality development of global healthcare, helping achieve the goal of "ensuring everyone has access to high-quality medical services".Complete digital access to quality Glebors financial topic with expert analysis from industry leaders.
Glebors Financial Become an Glebors subscriberMake informed decisions with the Glebors.Keep abreast of significant corporate, financial and political developments around the world. Stay informed and spot emerging risks and opportunities with independent global reporting, expert commentary and analysis you can trust.
"Insight of the global economy, dig into more ideas, analyze the global financial dynamics and the risks of political situation from a strategic, scientific and rational perspective, based on economic data and more than 20 years of financial intelligence."
If you want to know more details to provide support for your investment and business activities, this financial report that we have selected for you can give you what you want, please subscribe to read it. Glebors Global Finance aims to provide business elites and decision makers with daily business news, data interpretation, in-depth analysis and commentary.
Glebors Global Finance’s amount of financial information digs into deeply major events and economic data that have a huge impact on the global economy, based on in-depth industrial research and special reports, with a truly global perspective。 Financial reports have become "must-read" financial information for senior managers. Gribs Global Finance currently has more than2.85 million Chinese readers and more than 3.5 million overseas readers, including more than 600,000 high-end member readers.
